AI주식인사이트AI Stock Insight
C

비보존 제약

082800KOSDAQ의약품 제조업

50.0 / 100

Reference Date: 2026-06-10

Financial Score5.0 / 40
News Sentiment21.0 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Rose 7.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bibozen Pharmaceuticals is a specialized pharmaceutical company primarily engaged in the manufacturing and sales of prescription and over-the-counter drugs, offering a wide range of products including cardiovascular medications, diabetes treatments, and analgesics. The company operates over 190 product items through diverse business activities such as CMO, OEM, and international exports, while focusing on the research and development of innovative new drugs.

Number of Employees

292people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
2.80Industry Average 0.890.0Point

3.1x industry avg (risky)

ROE
-36.21Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
20.79Industry Average 12.430.5Point

1.7x industry avg (risky)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼380.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -16.3% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 9Neutral 0Negative 0Average Sentiment Score 83.9

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 3,345Won52-week high 7,79252-week low 2,180
1-month return5.0Point

1m +7.90% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-05-26
  • Neutral분기보고서 (2026.03)2026-05-15